EP4734984A1 - Composition pharmaceutique comprenant un sel d'acide fumarique de (+)-3-(2,3-difluorophényl)-3-méthoxypyrrolidine - Google Patents

Composition pharmaceutique comprenant un sel d'acide fumarique de (+)-3-(2,3-difluorophényl)-3-méthoxypyrrolidine

Info

Publication number
EP4734984A1
EP4734984A1 EP24737952.2A EP24737952A EP4734984A1 EP 4734984 A1 EP4734984 A1 EP 4734984A1 EP 24737952 A EP24737952 A EP 24737952A EP 4734984 A1 EP4734984 A1 EP 4734984A1
Authority
EP
European Patent Office
Prior art keywords
disorder
pharmaceutical composition
disease
tablet
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24737952.2A
Other languages
German (de)
English (en)
Inventor
Clas Sonesson
John CROALL
Richard Bell
Nicola PETERS
Matthew Ling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Integrative Research Laboratories Sweden AB
Original Assignee
Integrative Research Laboratories Sweden AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrative Research Laboratories Sweden AB filed Critical Integrative Research Laboratories Sweden AB
Publication of EP4734984A1 publication Critical patent/EP4734984A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant un sel de formule II. La composition pharmaceutique comprend des granules et est appropriée pour préparer une capsule ou un comprimé médicinal oral.
EP24737952.2A 2023-06-28 2024-06-28 Composition pharmaceutique comprenant un sel d'acide fumarique de (+)-3-(2,3-difluorophényl)-3-méthoxypyrrolidine Pending EP4734984A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23182150 2023-06-28
PCT/EP2024/068305 WO2025003437A1 (fr) 2023-06-28 2024-06-28 Composition pharmaceutique comprenant un sel d'acide fumarique de (+)-3-(2,3-difluorophényl)-3-méthoxypyrrolidine

Publications (1)

Publication Number Publication Date
EP4734984A1 true EP4734984A1 (fr) 2026-05-06

Family

ID=87036065

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24737952.2A Pending EP4734984A1 (fr) 2023-06-28 2024-06-28 Composition pharmaceutique comprenant un sel d'acide fumarique de (+)-3-(2,3-difluorophényl)-3-méthoxypyrrolidine

Country Status (3)

Country Link
EP (1) EP4734984A1 (fr)
CN (1) CN121511083A (fr)
WO (1) WO2025003437A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744308C (fr) 2008-11-24 2017-05-30 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Derives de 3-phenyl-3-methoxy-pyrrolidine en tant que modulateurs de la neurotransmission catecholaminergique corticale
EP3625213B1 (fr) 2017-05-19 2023-03-08 Integrative Research Laboratories Sweden AB Fumarate de (+)-3-(2,3-difluorophényl)-3-methoxypyrrolidine, son procédé de préparation et ses utilisations

Also Published As

Publication number Publication date
CN121511083A (zh) 2026-02-10
WO2025003437A1 (fr) 2025-01-02

Similar Documents

Publication Publication Date Title
JP7127101B2 (ja) ルカパリブの高投与力価錠剤
JP4757872B2 (ja) プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
KR20110117216A (ko) Ｒ-바클로펜 전구약물의 서방형 경구 투약 형태
US20210161823A1 (en) Solid oral dosage forms of eslicarbazepine
JP2025169294A (ja) カルバメート化合物を含む経口用医薬組成物及びその製造方法
AU2012288632B2 (en) New (trimethoxyphenylamino)pyrimidinyl formulations
US20260115169A1 (en) Pharmaceutical composition of darolutamide
RU2613192C1 (ru) Таблетки клозапина с пролонгированным высвобождением
US8173169B2 (en) Formulation and process for the preparation of modafinil
EP4734984A1 (fr) Composition pharmaceutique comprenant un sel d'acide fumarique de (+)-3-(2,3-difluorophényl)-3-méthoxypyrrolidine
EP2801350B1 (fr) Formulations pharmaceutiques de lacosamide
EP3939589A1 (fr) Comprimé à charge de médicament élevée comprenant du voxélotor
EP2968167A1 (fr) Forme dosifiée comprenant du crizotinib
WO2014157603A1 (fr) Composition pharmaceutique pour administration orale
WO2025032103A1 (fr) Compositions pharmaceutiques comprenant un sel de tartrate de n-[2-(3-fluoro-5-méthane-sulfonylphénoxy)éthyl](propyl)amine
HK40117315A (zh) 包含5-乙基-4-甲基-n-[4-[(2s)吗啉-2-基]苯基]-1h-吡唑-3-甲醯胺的药物组合物
JP2024520860A (ja) 固体剤形のメラトニン製剤
WO2019030773A1 (fr) Compositions de diclofénac à faible dose
HUE029193T2 (en) Delayed release drug formulations of thiocolchicoside
WO2007113371A1 (fr) Préparation pharmaceutique et méthode d'élaboration de ladite préparation
WO2017073738A1 (fr) Comprimé ayant comme principe actif la fexofénadine
EP1886684A1 (fr) Composition pharmaceutique comprenant du rimonabant
WO2017114597A1 (fr) Formes pharmaceutiques comprenant du ((cis)-n-(4-(diméthylamino) -1,4-diphénylcyclohexyl)-n-méthylcinnamamide
HK1149481A (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
HK1104974B (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE